~~<i id='BDB6D28D38'><strike id='BDB6D28D38'><tt id='BDB6D28D38'><pre id='BDB6D28D38'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：explore 2025-10-06 07:04:39 Page View：1

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Thursday approved the first medicine developed specifically to treat the serious liver disease known as MASH.

The pill, called Rezdiffra, is made by Madrigal Pharmaceuticals.

Metabolic dysfunction-associated steatohepatitis, or MASH, is often associated with obesity. The accumulation of fat in the liver causes inflammation, which leads to fibrosis, or liver scarring, and can progress in more advanced stages to cirrhosis, cancer, and the need for a liver transplant.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Pfizer plans to depart BIO
Next article： Drug repurposing or repositioning? The language matters

explore

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

CRISPR base editing slashes cholesterol levels in monkeys

Inanewexperiment,CRISPRbaseeditingslashedcholesterollevelsinmonkeysbytargetingtwogenesexpressedinthe

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

Setback for rare diseases as Taysha Gene Therapies pulls back

AdobeIn2020,asbiotechstockssurgedamidthepandemic,astartupcalledTayshaGeneTherapiesraisedover$300mill